Clinical trial
Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After Neoadjuvant Chemoradiotherapy in Resected Locally Advanced Esophageal Squamous Cell Carcinoma: an Exploratory Study
NCT05189730 is registered in ClinicalTrials.gov with Sichuan Cancer Hospital and Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After Neoadjuvant Chemoradiotherapy in Resected Locally Advanced Esophageal Squamous Cell Carcinoma: an Exploratory Study
- Lead sponsor
- Sichuan Cancer Hospital and Research Institute
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- July 1, 2021
- Completion date
- January 31, 2027
- Enrollment
- 80 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.